AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS
Latest Information Update: 08 Feb 2025
At a glance
- Drugs Dazukibart (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 29 Dec 2023 Status changed from active, no longer recruiting to completed.
- 10 Dec 2023 This trial has been completed in Poland (End Date: 20 Nov 2023), according to European Clinical Trials Database record.
- 15 Sep 2023 Planned End Date changed from 3 Dec 2023 to 24 Nov 2023.